The global market for Bacteriophage Therapy was valued at US$1.3 Billion in 2024 and is projected to reach US$1.5 Billion by 2030, growing at a CAGR of 2.4% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Bacteriophage Therapy market.
Phages can be custom-tailored to specific bacterial strains, making them especially valuable for treating chronic, biofilm-associated, or hospital-acquired infections such as Pseudomonas aeruginosa, Acinetobacter baumannii, and MRSA. Unlike broad-spectrum antibiotics, phage therapy preserves beneficial bacteria and can be used in combination with antibiotics for synergistic effects. The resurgence of interest is also being catalyzed by landmark compassionate use cases, regulatory openness to personalized therapies, and the growing urgency to expand the infectious disease treatment arsenal beyond chemically synthesized drugs.
Regulatory interest in flexible approval pathways - especially for personalized and compassionate use therapies - is accelerating clinical adoption. Agencies like the U.S. FDA and European Medicines Agency (EMA) are supporting investigational new drug (IND) applications and encouraging innovation through orphan drug designations and adaptive trial designs. Additionally, the establishment of phage banks and production platforms capable of rapid isolation and GMP-grade manufacturing is enabling scalable, standardized development models - bridging the gap between experimental treatment and broader commercialization.
Pharmaceutical and biotech firms are also targeting phage therapy for applications in agriculture and veterinary medicine, where overuse of antibiotics in livestock has accelerated resistance concerns. In parallel, microbiome restoration and targeted gut decolonization are emerging as novel frontiers for phage-based therapeutics. The food safety and sanitation sectors are exploring phage preparations as natural antibacterials to control pathogens like Listeria and Salmonella - opening non-clinical avenues for phage adoption.
Challenges such as narrow host range, regulatory complexity, and limited large-scale trial data remain, but are being actively addressed through personalized phage cocktails, bioinformatics-driven matching algorithms, and GMP-compliant phage manufacturing ecosystems. As AMR continues to threaten modern healthcare foundations, a pivotal question defines the path ahead: Can bacteriophage therapy evolve from last-resort intervention to front-line precision antimicrobial - integrating into clinical guidelines, manufacturing pipelines, and health system protocols as a next-generation solution to the antibiotic resistance crisis?
Segments: Targeted Bacteria (E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella, Other Targeted Bacterias); Disease Indication (Urinary Tract Infections, Chronic Otitis, Dental Extraction, Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications); Administration Route (Oral, Topical, Parenteral); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Bacteriophage Therapy Market - Key Trends & Drivers Summarized
Why Is Bacteriophage Therapy Re-Emerging as a Promising Alternative Amid the Global Antimicrobial Resistance Crisis?
Bacteriophage therapy - using viruses that selectively infect and destroy bacterial cells - is gaining renewed momentum as a viable alternative to traditional antibiotics, especially in the fight against multidrug-resistant (MDR) infections. As antimicrobial resistance (AMR) escalates into a global public health emergency, with conventional antibiotics becoming less effective against evolving pathogens, phage therapy offers a highly targeted approach that bypasses the collateral damage to the host microbiome and minimizes the risk of resistance proliferation.Phages can be custom-tailored to specific bacterial strains, making them especially valuable for treating chronic, biofilm-associated, or hospital-acquired infections such as Pseudomonas aeruginosa, Acinetobacter baumannii, and MRSA. Unlike broad-spectrum antibiotics, phage therapy preserves beneficial bacteria and can be used in combination with antibiotics for synergistic effects. The resurgence of interest is also being catalyzed by landmark compassionate use cases, regulatory openness to personalized therapies, and the growing urgency to expand the infectious disease treatment arsenal beyond chemically synthesized drugs.
How Are Genomic Tools, Synthetic Biology, and Regulatory Frameworks Advancing Phage Therapy Development?
Cutting-edge tools in genomics and synthetic biology are revolutionizing the development and precision of phage therapeutics. Whole-genome sequencing allows rapid identification of lytic phages and eliminates candidates with undesirable traits such as lysogeny or toxin genes. CRISPR and other gene editing techniques are being used to engineer phages with enhanced infectivity, broader host ranges, and resistance-mitigating capabilities. These bioengineered phages can target biofilm-producing pathogens, modulate host immune responses, and deliver therapeutic payloads in complex infection sites.Regulatory interest in flexible approval pathways - especially for personalized and compassionate use therapies - is accelerating clinical adoption. Agencies like the U.S. FDA and European Medicines Agency (EMA) are supporting investigational new drug (IND) applications and encouraging innovation through orphan drug designations and adaptive trial designs. Additionally, the establishment of phage banks and production platforms capable of rapid isolation and GMP-grade manufacturing is enabling scalable, standardized development models - bridging the gap between experimental treatment and broader commercialization.
Where Is Demand for Bacteriophage Therapy Growing and Which Applications Are Leading Clinical Focus?
Demand for bacteriophage therapy is growing globally, with active research hubs in the United States, Europe (notably Belgium, Poland, and France), Russia, and increasingly in Asia-Pacific countries such as India and South Korea. Clinical trials are expanding across therapeutic areas such as cystic fibrosis-associated infections, diabetic wound care, gastrointestinal disorders, and urinary tract infections (UTIs), where antibiotic failure rates are particularly high. Hospitals and academic centers are piloting phage therapy in ICU settings, burn units, and immunocompromised patient care as part of salvage treatments.Pharmaceutical and biotech firms are also targeting phage therapy for applications in agriculture and veterinary medicine, where overuse of antibiotics in livestock has accelerated resistance concerns. In parallel, microbiome restoration and targeted gut decolonization are emerging as novel frontiers for phage-based therapeutics. The food safety and sanitation sectors are exploring phage preparations as natural antibacterials to control pathogens like Listeria and Salmonella - opening non-clinical avenues for phage adoption.
What Is Fueling the Global Growth of the Bacteriophage Therapy Market?
The global growth of the bacteriophage therapy market is fueled by the urgent demand for alternative antimicrobials, advances in precision biology, and expanding public and private investment in AMR solutions. Supportive regulatory sentiment, rising venture capital in phage biotech startups, and international collaborations - such as the Phage Directory and Global Phage Initiative - are building a framework for innovation, clinical validation, and eventual market scalability. High-profile case studies demonstrating phage efficacy where antibiotics failed are further reinforcing public and medical interest.Challenges such as narrow host range, regulatory complexity, and limited large-scale trial data remain, but are being actively addressed through personalized phage cocktails, bioinformatics-driven matching algorithms, and GMP-compliant phage manufacturing ecosystems. As AMR continues to threaten modern healthcare foundations, a pivotal question defines the path ahead: Can bacteriophage therapy evolve from last-resort intervention to front-line precision antimicrobial - integrating into clinical guidelines, manufacturing pipelines, and health system protocols as a next-generation solution to the antibiotic resistance crisis?
Report Scope
The report analyzes the Bacteriophage Therapy market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Targeted Bacteria (E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella, Other Targeted Bacterias); Disease Indication (Urinary Tract Infections, Chronic Otitis, Dental Extraction, Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications); Administration Route (Oral, Topical, Parenteral); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the E. Coli segment, which is expected to reach US$364.7 Million by 2030 with a CAGR of a 1.8%. The Staphylococcus Aureus segment is also set to grow at 3.2% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $351.1 Million in 2024, and China, forecasted to grow at an impressive 4.5% CAGR to reach $281.7 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Bacteriophage Therapy Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Bacteriophage Therapy Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Bacteriophage Therapy Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Adaptive Phage Therapeutics, Armata Pharmaceuticals, Inc., BiomX Ltd., Biochimpharm, ContraFect Corporation and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 41 companies featured in this Bacteriophage Therapy market report include:
- Adaptive Phage Therapeutics
- Armata Pharmaceuticals, Inc.
- BiomX Ltd.
- Biochimpharm
- ContraFect Corporation
- Eligo Bioscience
- Eliava Biopreparations Ltd.
- Enbiotix, Inc.
- Fixed-Phage Ltd.
- InnoPhage Ltd.
- Intralytix, Inc.
- iNtODEWorld, Inc.
- Locus Biosciences, Inc.
- Micreos BV
- Microgen
- Nextbiotics
- OPTIPHARM Co., Ltd.
- PhagePro, Inc.
- Phagelux, Inc.
- Pherecydes Pharma
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What's Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Adaptive Phage Therapeutics
- Armata Pharmaceuticals, Inc.
- BiomX Ltd.
- Biochimpharm
- ContraFect Corporation
- Eligo Bioscience
- Eliava Biopreparations Ltd.
- Enbiotix, Inc.
- Fixed-Phage Ltd.
- InnoPhage Ltd.
- Intralytix, Inc.
- iNtODEWorld, Inc.
- Locus Biosciences, Inc.
- Micreos BV
- Microgen
- Nextbiotics
- OPTIPHARM Co., Ltd.
- PhagePro, Inc.
- Phagelux, Inc.
- Pherecydes Pharma
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 494 |
| Published | May 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 1.3 Billion |
| Forecasted Market Value ( USD | $ 1.5 Billion |
| Compound Annual Growth Rate | 2.4% |
| Regions Covered | Global |
